Login to Your Account



Pharma: Clinic Roundup


Friday, June 29, 2012
• Shire plc, of Dublin, Ireland, reported data showing that Vpriv (velaglucerase alfa for injection), its enzyme replacement therapy for Type I Gaucher disease, significantly improved selected markers of Gaucher-related bone disease in patients.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription